Literature DB >> 23814231

Acrodermatitis enteropathica-like skin lesions in a neonate.

Kamal Arora1, Rashmi Ranjan Das, Shasanka Shekhar Panda, Madhulika Kabra.   

Abstract

A male neonate was born to a sixth-gravida mother with a history of four early-neonatal deaths. On day 21 of life, the patient was admitted for poor feeding, vomiting and encephalopathy. Final diagnosis of propionic acidaemica (propionylcarnitine, 17.67 μmol/L) was made. He was managed by peritoneal dialysis followed by protein-free and special lipid diet, sodium benzoate and multivitamins. On day 28 of life, he developed acrodermatitis enteropathica-like skin lesions on perioral and diaper area that did not respond to oral zinc or antimicrobials. A possibility of acrodermatitis acidaemica was kept and supplementation with essential amino acids started, following which the skin lesions regressed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23814231      PMCID: PMC3703086          DOI: 10.1136/bcr-2013-200190

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Acrodermatitis acidemica secondary to malnutrition in glutaric aciduria type I.

Authors:  S Niiyama; S Koelker; I Degen; G F Hoffmann; R Happle; R Hoffmann
Journal:  Eur J Dermatol       Date:  2001 May-Jun       Impact factor: 3.328

2.  Acrodermatitis acidemica: experience of 5 years in Andalusia.

Authors:  J Dominguez-Cruz; M Bueno-Delgado; J Bernabeu-Wittel; C Delgado-Pecellin; J Conejo-Mir
Journal:  Pediatr Dermatol       Date:  2010 Mar-Apr       Impact factor: 1.588

3.  Acrodermatitis enerophatica-like skin lesions secondary to isoleucine deficiency.

Authors:  Javier J Domínguez-Cruz; Maria Bueno-Delgado; Jose Pereyra; Jose Bernabeu-Wittel; Julian Conejo-Mir
Journal:  Eur J Dermatol       Date:  2011 Jan-Feb       Impact factor: 3.328

4.  Acrodermatitis enteropathica-like cutaneous lesions in organic aciduria.

Authors:  L De Raeve; L De Meirleir; J Ramet; Y Vandenplas; E Gerlo
Journal:  J Pediatr       Date:  1994-03       Impact factor: 4.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.